Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Ratio: 2010-2020

Historic Equity Ratio for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2020 value amounting to 0.65.

  • Neurocrine Biosciences' Equity Ratio rose 24.65% to 0.67 in Q3 2021 from the same period last year, while for Sep 2021 it was 0.67, marking a year-over-year increase of 24.65%. This contributed to the annual value of 0.65 for FY2020, which is 33.13% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Equity Ratio of 0.65 as of FY2020, which was up 33.13% from 0.49 recorded in FY2019.
  • Neurocrine Biosciences' 5-year Equity Ratio high stood at 0.86 for FY2016, and its period low was 0.46 during FY2017.
  • Over the past 3 years, Neurocrine Biosciences' median Equity Ratio value was 0.49 (recorded in 2019), while the average stood at 0.54.
  • As far as peak fluctuations go, Neurocrine Biosciences' Equity Ratio slumped by 47.23% in 2017, and later skyrocketed by 33.13% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Equity Ratio (Yearly) stood at 0.86 in 2016, then slumped by 47.23% to 0.46 in 2017, then climbed by 6.35% to 0.48 in 2018, then rose by 0.74% to 0.49 in 2019, then surged by 33.13% to 0.65 in 2020.